BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16787504)

  • 1. Proteasome inhibition as novel treatment strategy in leukaemia.
    Vink J; Cloos J; Kaspers GJ
    Br J Haematol; 2006 Aug; 134(3):253-62. PubMed ID: 16787504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of the proteasome in leukaemia.
    McCloskey SM; McMullin MF; Walker B; Irvine AE
    Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Kelley TW; Alkan S; Srkalovic G; Hsi ED
    Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of proteasome inhibitors in the treatment of lung cancer.
    Bunn PA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors in lung cancer.
    Scagliotti G
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
    Abayomi EA; Sissolak G; Jacobs P
    Transfus Apher Sci; 2007 Aug; 37(1):85-92. PubMed ID: 17881293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR; Ovaa H
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.